Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus
about
Correlation of circulating CD27high plasma cells and disease activity in systemic lupus erythematosusA novel subset of memory B cells is enriched in autoreactivity and correlates with adverse outcomes in SLEB cell subsets and dysfunction of regulatory B cells in IgG4-related diseases and primary Sjögren's syndrome: the similarities and differencesB cells from rheumatoid arthritis patients show important alterations in the expression of CD86 and FcgammaRIIb, which are modulated by anti-tumor necrosis factor therapyReducing FLI1 levels in the MRL/lpr lupus mouse model impacts T cell function by modulating glycosphingolipid metabolismA small CD11b(+) human B1 cell subpopulation stimulates T cells and is expanded in lupusEfficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system.Targeting CD40L: a promising therapeutic approach.Type I interferon-dependent CD86(high) marginal zone precursor B cells are potent T cell costimulators in miceBalancing diversity and tolerance: lessons from patients with systemic lupus erythematosus.Preferential Induction of the T Cell Auxiliary Signaling Molecule B7-H3 on Synovial Monocytes in Rheumatoid ArthritisAn antibody-based leukocyte-capture microarray for the diagnosis of systemic lupus erythematosus.Reduced proportions of natural killer T cells are present in the relatives of lupus patients and are associated with autoimmunity.Peripheral B cell abnormalities and disease activity in systemic lupus erythematosus.Regulators of B-cell activity in SLE: a better target for treatment than B-cell depletion?The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant.Translational Mini-Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren's syndrome: clinical implications and effects of B cell-targeted therapies.Use of biomarkers in the management of children with lupus.Immune alterations in malignant melanoma and current immunotherapy concepts.Update on B-cell targeted therapies for systemic lupus erythematosus.Current role of rituximab in systemic lupus erythematosus.Changes in immunological profile as a function of urbanization and lifestyle.B cells from African American lupus patients exhibit an activated phenotype.Pharmacokinetic, Pharmacodynamic, and Safety Profile of a Novel Anti-CD28 Domain Antibody Antagonist in Healthy Subjects.Hydroxychloroquine inhibits CD154 expression in CD4+ T lymphocytes of systemic lupus erythematosus through NFAT, but not STAT5, signalingProcainamide-induced autoimmunity: Relationship to T-helper 2-type T-cell activation.Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus.Decreased CD1d level is associated with CD86 over-expression in B cells from systemic lupus erythematosus.Peripheral circulating activated b-cell populations are associated with nephritis and disease activity in patients with systemic lupus erythematosus.Abnormalities of CD4 T cell subpopulations in ANCA-associated vasculitis.Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus
P2860
Q28269798-1F2E13EF-61F3-412D-90B4-38EA6A854A20Q33614719-44099943-39E1-475D-B4D2-299FC593F867Q33822678-53769B97-5355-471E-ADC5-3953242488C6Q33923459-71753F1A-65D8-4F11-A356-A01067B1A76CQ34990559-54D9E3A1-0073-42AC-8C5F-0CF011F9F3DCQ35627702-17BCD069-4847-449B-8AD3-77B461DE9D60Q35760171-9AAC1311-A15B-4DF7-9ACD-EB768F90F6D3Q35830859-DDE92520-85E2-41D6-ACB8-40BF69F1416EQ35848476-C1CADD0B-29E8-40C7-9152-223BF4766B37Q36215324-1186E1B4-017E-4BF5-B417-79EA98943949Q36594694-E78EC907-E780-4D97-A039-6B0623B9E0ABQ36680912-89B9326B-8741-434D-82BB-D892C98A4CE5Q36993238-D5BB77B6-A658-43E0-9E3B-0D78D64B4D5EQ37333433-33E161E5-DF78-4DA4-BA83-B96488911BBAQ37477848-AFE3B98B-95C8-4F60-841C-5BF223B17BC6Q37689179-0FED0C08-7EB0-47A8-BDC8-87EA5476D253Q37963474-8E9EF85A-3211-4E9F-A25A-5E16ABD0F9B4Q38077151-7146C636-7910-45BD-BA93-34DC17799333Q38127733-22852AF4-F977-4A6F-957A-4E47B9FDDCC0Q38192656-B31C7406-4471-4D83-95DC-C4FDA239E81FQ38293284-E70F176F-81A5-4B76-BDA4-DB1E862067B9Q39230263-62BC80F3-2600-4558-8819-9C344D7B32FDQ39325816-90788160-FD2F-4003-A4A4-132E3DCFE479Q40617738-5E946E81-1CA2-4D88-A009-D16717EA5F6AQ41336601-FCD453F8-E9CA-489E-8C6E-E58094C2CFC5Q46331275-54E28F88-7AAC-48CA-BA40-F2C820FA3783Q47913418-CF7C1BD4-E04C-4031-8CF8-82E0DDEE9F42Q51088258-645DD75B-D308-476D-B9C3-53C23519C036Q51737611-655FB583-0E6A-492E-AE0E-363B14170BADQ51993610-717FEE17-840A-48A8-9950-1687FFD5FE15Q56902724-63DE52EC-3189-48CE-A145-F645B937F46C
P2860
Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Expression of costimulatory mo ...... h systemic lupus erythematosus
@ast
Expression of costimulatory mo ...... h systemic lupus erythematosus
@en
type
label
Expression of costimulatory mo ...... h systemic lupus erythematosus
@ast
Expression of costimulatory mo ...... h systemic lupus erythematosus
@en
prefLabel
Expression of costimulatory mo ...... h systemic lupus erythematosus
@ast
Expression of costimulatory mo ...... h systemic lupus erythematosus
@en
P2093
P356
P1476
Expression of costimulatory mo ...... h systemic lupus erythematosus
@en
P2093
P304
P356
10.1136/ARD.60.5.523
P407
P577
2001-05-01T00:00:00Z